Hi cortinaboy, thanks for your informative/level headed posts as per usual. Keen to understand your thoughts on the quality of the result itself. I recall one of the analysts on the call today (not sure if you were listening) said words to the effect of it being at the 'low end of the quality spectrum' as far as successful clinical trials go given 3/6 indications were met and only the higher dose succeeded. Did you have any thoughts on that? I know mgt have said overall the trial exceeded expectations and they commented on difficulty/complexity etc, but thought maybe the fact the result wasn't a complete lay down may have held it back? Appreciate your thoughts to someone who is not a bio expert! Corgi.
Observing..., page-3
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.72 |
Change
-0.240(1.15%) |
Mkt cap ! $2.645B | |||
| Open | High | Low | Value | Volume |
| $21.00 | $21.21 | $20.31 | $15.80M | 766.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $20.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.72 | 3108 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.75 |
Change
-0.240 ( 1.47 %) |
||||
| Open | High | Low | Volume | ||
| $20.97 | $21.15 | $20.32 | 199599 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| NEU (ASX) Chart |